
iRhythm Technologies (IRTC) Stock Forecast & Price Target
iRhythm Technologies (IRTC) Analyst Ratings
Bulls say
iRhythm Technologies Inc. has demonstrated a positive financial trajectory, with its 2025 revenue guidance increased to $735M-$740M, reflecting a strong year-over-year growth rate of 24.6% at the midpoint. The company's adjusted gross margin also saw an improvement, rising to 71.1%, surpassing consensus expectations and indicating enhanced operational efficiency. Additionally, iRhythm's ongoing expansion in international markets, particularly in Japan and the UK, along with increased revenue estimates driven by a robust core business and innovative product offerings, further solidifies a favorable outlook for the company's financial performance.
Bears say
iRhythm Technologies faces a challenging financial outlook due to projected growth slowing to the low-teens, coupled with persistent net losses and potential operational disruptions. Key risks include the impact of regulatory scrutiny from the Department of Justice and the FDA, fluctuating reimbursement policies, and increasing competition that could limit market share and profitability. Additionally, the company's reliance on physician adoption of its Zio service and the competitive nature of the ambulatory cardiac monitoring market further contribute to concerns regarding its future commercial performance and overall financial stability.
This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.
iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction
Start investing in iRhythm Technologies (IRTC)
Order type
Buy in
Order amount
Est. shares
0 shares